Progress against childhood cancer: The Pediatric Oncology Group experience

T. J. Vietti; V. Land; J. J. Shuster; M. Amylon; M. Link; C. Berard; W. Crist; M. Borowitz; J. Falletta; W. P. Bowman; M. Brecher; R. Castleberry; L. Frankel; A. Goorin; F. A. Hayes; E. Hvizdala; J. P. Krischer; Bradley H Pollock; N. McWilliams

Progress against childhood cancer: The Pediatric Oncology Group experience

T. J. Vietti, V. Land, J. J. Shuster, M. Amylon, M. Link, C. Berard, W. Crist, M. Borowitz, J. Falletta, W. P. Bowman, M. Brecher, R. Castleberry, L. Frankel, A. Goorin, F. A. Hayes, E. Hvizdala, J. P. Krischer, Bradley H Pollock, N. McWilliams

Research output: Contribution to journal › Article

45 Scopus citations

Abstract

The sequential outcome was evaluated for all childhood cancers in which the Pediatric Oncology Group has conducted a series of clinical trials, with constant eligibility, on patients with newly diagnosed cancer. The analysis was applied to more than 7000 patients with cancer diagnosed between 1976 and 1989. These include acute leukemia (4 subgroups), non-Hodgkins lymphoma (4 subgroups), osteogenic sarcoma, and advanced neuroblastoma. In 8 of these 10 disease areas, significant improvement in outcome has occurred. In rare diseases such as pediatric cancer, collaborative studies may be the only way to conduct therapeutic trials of sufficient statistical power. A cooperative group has distinct advantages over a series of ad hoc collaborative studies in that it can maintain a unified data base, study its history with minimal confounding effects of changing institutional participants, and develop long- term research relationships among its participants.

Original language	English (US)
Pages (from-to)	597-600
Number of pages	4
Journal	Pediatrics
Volume	89
Issue number	4
State	Published - 1992
Externally published	Yes

Keywords

cancer
cooperative group
neoplasm

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

Fingerprint Dive into the research topics of 'Progress against childhood cancer: The Pediatric Oncology Group experience'. Together they form a unique fingerprint.

Cite this

Vietti, T. J., Land, V., Shuster, J. J., Amylon, M., Link, M., Berard, C., Crist, W., Borowitz, M., Falletta, J., Bowman, W. P., Brecher, M., Castleberry, R., Frankel, L., Goorin, A., Hayes, F. A., Hvizdala, E., Krischer, J. P., Pollock, B. H., & McWilliams, N. (1992). Progress against childhood cancer: The Pediatric Oncology Group experience. Pediatrics, 89(4), 597-600.

Progress against childhood cancer : The Pediatric Oncology Group experience. / Vietti, T. J.; Land, V.; Shuster, J. J.; Amylon, M.; Link, M.; Berard, C.; Crist, W.; Borowitz, M.; Falletta, J.; Bowman, W. P.; Brecher, M.; Castleberry, R.; Frankel, L.; Goorin, A.; Hayes, F. A.; Hvizdala, E.; Krischer, J. P.; Pollock, Bradley H; McWilliams, N.

In: Pediatrics, Vol. 89, No. 4, 1992, p. 597-600.

Research output: Contribution to journal › Article

Vietti, T. J. ; Land, V. ; Shuster, J. J. ; Amylon, M. ; Link, M. ; Berard, C. ; Crist, W. ; Borowitz, M. ; Falletta, J. ; Bowman, W. P. ; Brecher, M. ; Castleberry, R. ; Frankel, L. ; Goorin, A. ; Hayes, F. A. ; Hvizdala, E. ; Krischer, J. P. ; Pollock, Bradley H ; McWilliams, N. / Progress against childhood cancer : The Pediatric Oncology Group experience. In: Pediatrics. 1992 ; Vol. 89, No. 4. pp. 597-600.

@article{141c4aec84ff45e5b45289f1ebb366da,

title = "Progress against childhood cancer: The Pediatric Oncology Group experience",

abstract = "The sequential outcome was evaluated for all childhood cancers in which the Pediatric Oncology Group has conducted a series of clinical trials, with constant eligibility, on patients with newly diagnosed cancer. The analysis was applied to more than 7000 patients with cancer diagnosed between 1976 and 1989. These include acute leukemia (4 subgroups), non-Hodgkins lymphoma (4 subgroups), osteogenic sarcoma, and advanced neuroblastoma. In 8 of these 10 disease areas, significant improvement in outcome has occurred. In rare diseases such as pediatric cancer, collaborative studies may be the only way to conduct therapeutic trials of sufficient statistical power. A cooperative group has distinct advantages over a series of ad hoc collaborative studies in that it can maintain a unified data base, study its history with minimal confounding effects of changing institutional participants, and develop long- term research relationships among its participants.",

keywords = "cancer, cooperative group, neoplasm",

author = "Vietti, {T. J.} and V. Land and Shuster, {J. J.} and M. Amylon and M. Link and C. Berard and W. Crist and M. Borowitz and J. Falletta and Bowman, {W. P.} and M. Brecher and R. Castleberry and L. Frankel and A. Goorin and Hayes, {F. A.} and E. Hvizdala and Krischer, {J. P.} and Pollock, {Bradley H} and N. McWilliams",

year = "1992",

language = "English (US)",

volume = "89",

pages = "597--600",

journal = "Pediatrics",

issn = "0031-4005",

publisher = "American Academy of Pediatrics",

number = "4",

}

TY - JOUR

T1 - Progress against childhood cancer

T2 - The Pediatric Oncology Group experience

AU - Vietti, T. J.

AU - Land, V.

AU - Shuster, J. J.

AU - Amylon, M.

AU - Link, M.

AU - Berard, C.

AU - Crist, W.

AU - Borowitz, M.

AU - Falletta, J.

AU - Bowman, W. P.

AU - Brecher, M.

AU - Castleberry, R.

AU - Frankel, L.

AU - Goorin, A.

AU - Hayes, F. A.

AU - Hvizdala, E.

AU - Krischer, J. P.

AU - Pollock, Bradley H

AU - McWilliams, N.

PY - 1992

Y1 - 1992

N2 - The sequential outcome was evaluated for all childhood cancers in which the Pediatric Oncology Group has conducted a series of clinical trials, with constant eligibility, on patients with newly diagnosed cancer. The analysis was applied to more than 7000 patients with cancer diagnosed between 1976 and 1989. These include acute leukemia (4 subgroups), non-Hodgkins lymphoma (4 subgroups), osteogenic sarcoma, and advanced neuroblastoma. In 8 of these 10 disease areas, significant improvement in outcome has occurred. In rare diseases such as pediatric cancer, collaborative studies may be the only way to conduct therapeutic trials of sufficient statistical power. A cooperative group has distinct advantages over a series of ad hoc collaborative studies in that it can maintain a unified data base, study its history with minimal confounding effects of changing institutional participants, and develop long- term research relationships among its participants.

AB - The sequential outcome was evaluated for all childhood cancers in which the Pediatric Oncology Group has conducted a series of clinical trials, with constant eligibility, on patients with newly diagnosed cancer. The analysis was applied to more than 7000 patients with cancer diagnosed between 1976 and 1989. These include acute leukemia (4 subgroups), non-Hodgkins lymphoma (4 subgroups), osteogenic sarcoma, and advanced neuroblastoma. In 8 of these 10 disease areas, significant improvement in outcome has occurred. In rare diseases such as pediatric cancer, collaborative studies may be the only way to conduct therapeutic trials of sufficient statistical power. A cooperative group has distinct advantages over a series of ad hoc collaborative studies in that it can maintain a unified data base, study its history with minimal confounding effects of changing institutional participants, and develop long- term research relationships among its participants.

KW - cancer

KW - cooperative group

KW - neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0026588052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026588052&partnerID=8YFLogxK

M3 - Article

C2 - 1557237

AN - SCOPUS:0026588052

VL - 89

SP - 597

EP - 600

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -